Home Featured Page 252

Featured

Latest

Toad, Truth, and the Trouble with 5-MeO: Why Bufo alvarius Needs Our Protection

One Year After FDA’s MDMA Rejection: Insiders and Observers Reflect

From Huxley to Heffter: Mark Geyer Reflects on a Life in Psychedelic Research

Advanced Shadow Work and Psychedelic Integration: A Jungian Path to Wholeness

Numinus Wellness Q2 2021 Results Highlighted by $17.25 Million Financing, Mindspace...

Op-Ed: Re-evaluating the Results of the Recent Trial of Psilocybin vs...

Bexson Biomedical Granted USPTO Patent On Proprietary Ketamine Formulation

Tryp Therapeutics Announces Q2 2021 Financial Results

Small Pharma Completes Reverse Take-Over Transaction

MINDCURE Shares Update on Strong Financial Position, Near Term Revenue Drivers...

Lobe Sciences Announces Filing of PCT Application

BetterLife Files Patent for Invention of Novel Subcutaneous Implant to Prevent...

Mindset Pharma Announces Positive Preclinical Results of Its Proprietary Next Generation...

Delix Therapeutics Co-Founder Publishes Groundbreaking Study Demonstrating Therapeutic Potential for a...

1...251252253...295 Page 252 of 295

Toad, Truth, and the Trouble with 5-MeO: Why Bufo alvarius Needs...

One Year After FDA’s MDMA Rejection: Insiders and Observers Reflect

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Toad, Truth, and the Trouble with 5-MeO: Why Bufo alvarius Needs Our Protection

One Year After FDA’s MDMA Rejection: Insiders and Observers Reflect

Harry Pack NFT – Last Call

From Huxley to Heffter: Mark Geyer Reflects on a Life in Psychedelic Research

Advanced Shadow Work and Psychedelic Integration: A Jungian Path to Wholeness

Numinus Wellness Q2 2021 Results Highlighted by $17.25 Million Financing, Mindspace...

Op-Ed: Re-evaluating the Results of the Recent Trial of Psilocybin vs...

Bexson Biomedical Granted USPTO Patent On Proprietary Ketamine Formulation

Tryp Therapeutics Announces Q2 2021 Financial Results

Small Pharma Completes Reverse Take-Over Transaction

MINDCURE Shares Update on Strong Financial Position, Near Term Revenue Drivers...

Lobe Sciences Announces Filing of PCT Application

BetterLife Files Patent for Invention of Novel Subcutaneous Implant to Prevent...

Mindset Pharma Announces Positive Preclinical Results of Its Proprietary Next Generation...

Delix Therapeutics Co-Founder Publishes Groundbreaking Study Demonstrating Therapeutic Potential for a...

EDITOR PICKS

Toad, Truth, and the Trouble with 5-MeO: Why Bufo alvarius Needs...

One Year After FDA’s MDMA Rejection: Insiders and Observers Reflect

Harry Pack NFT – Last Call

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY